Sinovac Biotech (SVA)
(Delayed Data from NSDQ)
$6.47 USD
0.00 (0.00%)
Updated Feb 22, 2019 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SVA 6.47 0.00(0.00%)
Will SVA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SVA based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for SVA
Orbimed Advisors LLC Adjusts Holdings in PMV Pharmaceuticals Inc
Sernova Biotherapeutics to Present at Global Investment Conference
Orbimed Advisors LLC Acquires Significant Stake in Shattuck Labs Inc
SINOVAC Board Sets the Record Straight on July 8 Special Meeting of Shareholders | SVA Stock News
Newly Elected Directors of Sinovac Hold the First Board Meeting | SVA Stock News